ReviewFrontiers in oncology2026
Head and neck cancer therapeutic vaccines: a review.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck squamous cell carcinoma (HNSCC) accounts for nearly one million new cases of cancer and approximately one half million deaths worldwide each year. The complexity of the tumor microenvironment, the lack of actionable target mutations as well as the increasing resistance of HNSCC to innate immunity pose challenges for development of effective treatment. Personalized cancer vaccines are emerging as a promising treatment strategy in HNSCC. Combining immune checkpoint inhibitor therapy with therapeutic cancer vaccines can enhance immune activation through stimulation of both innate and adaptive immune responses. The ability of therapeutic vaccines to illicit a robust immune response remains promising, however achieving consistent and durable clinical outcome remains a key challenge. In this article, we review the current and emerging strategies in therapeutic vaccination, with a particular focus on personalized cancer vaccines in the treatment of HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.